Zymeworks Inc. (ZYME) Q1 2026 Earnings Call Transcript

Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates

Zymeworks (ZYME) delivered earnings and revenue surprises of -510.13% and -94.63%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced results from the dose-escalation part of the Phase 1 study for ZW191, a folate receptor alpha (FR?)-targeting antibody-drug conjugate (ADC), at the 2026 American Association for Cancer Research (AACR) Annual Meeting.

Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FR?-Targeting Antibody-Drug Conjugate

VANCOUVER, British Columbia, March 30, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ZW191, an antibody-drug conjugate (ADC) targeting folate receptor-? (FR?), for the treatment of patients with advanced or metastatic platinum-res...

Zymeworks: H.C. Wainwright begrüßt die strategische Neuausrichtung - Experten heben Kursziel an und sehen nun 85 % Potenzial

Zymeworks (ZYME) hat Anfang März 2026 einen entscheidenden Schritt zur langfristigen finanziellen Absicherung gemacht, indem das Unternehmen eine durch Lizenzgebühren besicherte Finanzierung in Höhe...

Wer Biotechnologie-Aktien sucht, muss jetzt Zymeworks auf dem Schirm haben!

Zymeworks sollte man als Trader jetzt auf dem Schirm haben. Es handelt sich um ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung neuartiger, multifunktionaler Antikörper-Therapien zur...

Zymeworks outlines $1.5B milestone potential and signals milestone-driven expansion strategy through 2028

Zymeworks Inc. (ZYME) Q4 2025 Earnings Call Transcript

Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing

NEW YORK and VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Zymeworks Inc. (Nasdaq: ZYME) today announced an agreement for $250 million in funding from Royalty Pharma in the form of a non-recourse royalty-backed note with repayments due from 30% of worldwide tiered royalties on Ziihera® (zanidatamab-hrii) owed to Zymeworks from Jazz Pharmaceuticals (Jazz) and BeOne Medicines (BeOne).

Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

VANCOUVER, British Columbia and NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) and Royalty Pharma plc (Nasdaq: RPRX) today announced an agreement for $250 million in funding from Royalty Pharma in the form of a non-recourse royalty-backed note with repayments due from 30% of worldwide tiered royalties on Ziihera® (zanidatamab-hrii) owed to Zymeworks from Jazz Pharmaceuticals (Jazz) and BeOne Medicines (BeOne).

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today reported financial results for the fourth quarter and year ended December 31, 2025 and provided a summary of recent business highlights.

Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year

This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships.

Zymeworks Outlines Strategic Priorities and Outlook for 2026

VANCOUVER, British Columbia, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today outlined its strategic priorities and key milestones for 2026. Following a year of significant clinical, operational and financial progress, Zymeworks is focused on executing a long-term strategy designed to maximize value creation for patient...

Zymeworks Inc. (ZYME) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics today announced the appointment of Scott Platshon as Acting Chief Investment Officer. Mr. Platshon will report directly to Zymeworks’ Chair and Chief Executive Officer, Kenneth Galbraith, and work closely with him to manage expected future cash flows f

Stocks making the biggest moves premarket: Alphabet, Zymeworks, lithium producers, Quantum Computing, Clearwater Analytics and more

These are some of the stocks posting the largest moves in premarket trading.

Zymeworks Inc. (ZYME) is a Great Momentum Stock: Should You Buy?

Does Zymeworks Inc. (ZYME) have what it takes to be a top stock pick for momentum investors? Lets find out.

Zymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue Estimates

Zymeworks (ZYME) delivered earnings and revenue surprises of +105.77% and +256.65%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

VANCOUVER, British Columbia, May 30, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that the National Medical Products Administration (NMPA) in China has approved zanidatamab for the treatment of patients with previously treated, unresectabl...

Zymeworks Inc. (ZYME) Q1 2025 Earnings Call Transcript

Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates

Zymeworks (ZYME) delivered earnings and revenue surprises of 33.33% and 57.36%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zymeworks Inc. (ZYME) Q4 2024 Earnings Call Transcript

Zymeworks Inc. 2024 Q4 - Results - Earnings Call Presentation

Zymeworks Inc. (ZYME) Reports Q4 Loss, Misses Revenue Estimates

Zymeworks (ZYME) delivered earnings and revenue surprises of 3.12% and 15.54%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Ecor1 capital increases stake in Zymeworks with $1.88 million purchase By Investing.com

Ecor1 capital increases stake in Zymeworks with $1.88 million purchase

Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases

VANCOUVER, British Columbia, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced highlights from its R&D Day reviewing the Company’s development progress on its wholly-owned pipeline assets and expansion into new therapeutic areas in hematological cancers and autoimmune and inflammatory disea...

Zymeworks Inc. 2024 Q3 - Results - Earnings Call Presentation

Zymeworks Inc. (ZYME) Q3 2024 Earnings Call Transcript

Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

VANCOUVER, British Columbia, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced new preclinical data for Zymeworks’ antibody-drug conjugate (ADC) candidates ZW220 and ZW251 in presentations at the European Organisation for Research and Treatment of Cancer-National Cancer Institute-American A...

Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks’ proprietary antibody-drug conjugate development platforms Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks’ proprietary antibody-drug conjugate development platforms